Pfizer is making headlines with its $7.3 billion acquisition of Metsera, a weight loss drugmaker, as it aims to capture a share of the booming obesity drug market. This deal highlights the growing demand for innovative obesity treatments and Pfizer's strategic pivot following setbacks in its own drug pipeline.
Lilly's new oral pill, Orforglipron, has shown promising results in reducing weight and improving blood sugar levels in diabetes patients. With nearly 4% rise in shares, the drug is on track for FDA approval.
A groundbreaking study shows that bariatric surgery leads to five times more weight loss than GLP-1 drugs like semaglutide. Discover why surgery remains the gold standard in obesity treatment.
A new regulator confirmation links Ozempic to a rare eye condition, NAION, affecting diabetes patients. This revelation raises concerns about potential blindness risks associated with semaglutide. Discover the implications for users.
Recent clinical trials show that GLP-1 weight loss medications like Zepbound are more effective for women than men, prompting researchers to explore the biological and societal reasons behind this phenomenon.
In a groundbreaking clinical trial, Mounjaro proves to be nearly 50% more effective than Ozempic. This article explores the implications of this major breakthrough in weight loss treatments.
A groundbreaking trial reveals that Mounjaro is more effective than Wegovy for weight loss, achieving a 20% reduction over 72 weeks compared to Wegovy's 14%. Discover the implications for obesity treatment!
A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
Eli Lilly introduces discounted higher doses of the weight loss drug Zepbound in a move to make the treatment more accessible to uninsured patients and address the growing demand for obesity treatments.
